CAMBRIDGE, Mass.--(BUSINESS WIRE)--TransMolecular, Inc. today announced the presentation of data from a completed clinical study utilizing radiolabeled TM601, demonstrating highly specific tumor uptake of intravenously administered 131I-TM601 in several different primary and metastatic solid tumors, including glioma, melanoma, lung, prostate, colon, breast, and pancreatic cancers. Additionally, the study demonstrated that 131I-TM601 localized to tumors across the blood-brain barrier. The data were highlighted in an oral presentation at the Society for Nuclear Medicine (SNM) Annual Meeting. TM601 is a novel, wholly synthetic peptide found to have robust anti-angiogenic activity in neovascular diseases, including cancer and ophthalmic disease, as well as tumor-targeting capabilities.
